Monaca C, Duhamel A, Jacquesson J M, Ozsancak C, Destée A, Guieu J D, Defebvre L, Derambure P
Service de Neurophysiologie Clinique, EA2683, Hôpital R. Salengro, CHRU de Lille, F-59037 Lille Cedex, France.
Sleep Med. 2006 Aug;7(5):448-53. doi: 10.1016/j.sleep.2005.12.002. Epub 2006 Jun 5.
To assess the prevalence of vigilance disorders in Parkinson's disease patients, relate the observed phenomena to potential causes and confirm these troubles with polysomnographic analysis.
A questionnaire was used to gather information on demographic data, previous and current treatments, disease characteristics, sleep and vigilance troubles. Somnolence was measured using the Epworth Sleepiness Scale (ESS). Nocturnal polysomnography (PSG) and multiple sleep latency tests (MSLT) were performed for a sample of parkinsonian patients.
Two hundred twenty-two parkinsonian patients completed the questionnaire, and 36 patients had objective analyses. Of the patients, 43.2% had an ESS score >10, and 28.4% reported somnolence in the hour after taking dopaminergic drugs, whereas 6.8% reported unintended sleep episodes. In view of questionnaire data, these vigilance disorders may be partly explained not only by the impact of nocturnal sleep disorders (e.g. sleep apnea syndromes) but also by dopaminergic therapy (especially with dopaminergic agonists). With PSG and MSLT results, we have shown a significant correlation between mean sleep latency and ESS score. Patients with unintended sleep episodes have severe sleepiness in MSLT compared with others patients.
Vigilance disorders are frequently observed in Parkinson's disease. We recommend informing patients of the risk of occurrence of such conditions, notably for patients with unintended sleep episodes and with sleepiness in the hour after taking dopaminergic drugs.
评估帕金森病患者警觉障碍的患病率,将观察到的现象与潜在病因相关联,并通过多导睡眠图分析证实这些问题。
使用问卷收集有关人口统计学数据、既往及当前治疗、疾病特征、睡眠和警觉问题的信息。使用爱泼华嗜睡量表(ESS)测量嗜睡程度。对一组帕金森病患者进行夜间多导睡眠图(PSG)和多次睡眠潜伏期测试(MSLT)。
222名帕金森病患者完成了问卷,36名患者进行了客观分析。在这些患者中,43.2%的ESS评分>10,28.4%的患者报告在服用多巴胺能药物后1小时内嗜睡,而6.8%的患者报告有意外睡眠发作。根据问卷数据,这些警觉障碍不仅可能部分由夜间睡眠障碍(如睡眠呼吸暂停综合征)的影响所致,还可能与多巴胺能治疗(尤其是使用多巴胺能激动剂)有关。根据PSG和MSLT结果,我们发现平均睡眠潜伏期与ESS评分之间存在显著相关性。与其他患者相比,有意外睡眠发作的患者在MSLT中存在严重嗜睡。
帕金森病患者经常出现警觉障碍。我们建议告知患者发生此类情况的风险,特别是对于有意外睡眠发作以及在服用多巴胺能药物后1小时内嗜睡的患者。